ENTPD1 and neoplasm: Systemic administration (intraperitoneal, i.p.)of the mCD39-specific ASO in MC38 tumor bearing mice resulted in a specific and dose-dependent downregulation of CD39 protein in tumor infiltrating CD4+ Tregs as well as TAMs (Fig. 4c, d and Additional file 5: Figure S3A).